Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
tozinameran (Pfizer)
- Development stage
- Approved
- Lead developer
- BioNTech
- Modality
- mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
Tozinameran (BNT162b2) is a nucleoside-modified messenger RNA (mRNA) vaccine developed by BioNTech in collaboration with Pfizer for the prevention of COVID-19. It consists of mRNA encoding the full-length SARS-CoV-2 spike protein, encapsulated in lipid nanoparticles (LNPs). Upon intramuscular injection, the LNPs facilitate the entry of mRNA into host cells, where it is translated into the spike protein. This protein then triggers an immune response, including the production of neutralizing antibodies and T-cell activation, providing protection against subsequent infection by the SARS-CoV-2 virus. It was the first COVID-19 vaccine to receive emergency use authorization and full approval in several countries.
- Brand names
- Comirnaty
- Other names
- Pfizer-BioNTech COVID-19 VaccinePfizer-BioNTech
02
Targets
SARS-CoV-2 spikeACE2 (Angiotensin-converting enzyme 2)Cellular lipid membranes and endosomal lipids
Beyond the preview
Go deeper on tozinameran (Pfizer).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on tozinameran (Pfizer).